18F-LNC1007

This study is a single-arm, single-center trial aimed at evaluating the pharmacokinetics, bio-distribution, dosimetry, and safety of 18F-LNC1007 injection in healthy volunteers and light tumor burden cancer patients, as defined by <5 lesions on a conventional PET/CT done for clinical purposes and molecular imaging tumor volume of <10ml.
All participants must provide a signed consent form before enrolling in the trial.
For each participant, the study duration will be about 3 weeks including 2 weeks' screening, 1 week of scanning and safety follow-up.

评价 18F-LNC1007 注射液 PET/CT 对肾透明细胞癌远处转移的诊断效能。